Furthermore, mutations that result in a loss of SPOP function disrupt the PD-L1 degradation, resulting in heightened levels of PD-L1 and a decrease in the number of tumor-infiltrating lymphocytes in both mouse tumors and prostate cancer tissues. Here, CD274 is linked to prostate carcinoma.